School of Public Health (Shenzhen), Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Engineering Technology Center of Nutrition Transformation, Sun Yat-sen University, Guangzhou, Guangdong, China.
Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Sun Yat-sen University, Guangzhou, Guangdong, China; Guangdong Engineering Technology Center of Nutrition Transformation, Sun Yat-sen University, Guangzhou, Guangdong, China; Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, China.
Clin Nutr. 2021 Apr;40(4):1871-1878. doi: 10.1016/j.clnu.2020.10.014. Epub 2020 Oct 15.
BACKGROUND & AIMS: Plasma ceramides have been identified as novel risk factors for metabolic and cardiovascular diseases. We aimed to evaluate the effects of dietary anthocyanins on plasma ceramides and to disentangle whether the alterations in ceramides could be related with those in other cardiometabolic risk factors in the dyslipidemia.
In a randomized double-blinded placebo-controlled trial, 176 eligible dyslipidemia subjects were randomly assigned into four groups receiving placebo, 40, 80, or 320 mg/day anthocyanins, respectively for 12 weeks.
A total of 169 subjects completed the study. After 12-week intervention, dietary anthocyanins dose-dependently reduced plasma concentrations of all six ceramide species in the dyslipidemia subjects (all P values < 0.05). Specifically, 320 mg/day anthocyanins effectively lowered plasma N-palmitoylsphingosine (Cer 16:0, mean change: -28.3 ± 41.2 versus 2.9 ± 38.2, nmol/L, P = 0.018) and N-tetracosanoylsphingosine (Cer 24:0, mean change: -157.1 ± 493.9 versus 10.7 ± 439.9, nmol/L, P = 0.002) compared with the placebo. The declines in plasma Cer 16:0 and Cer 24:0 were significantly correlated with the decreases in plasma non-high-density lipoprotein cholesterol (nonHDL-C, Spearman's r = 0.32, P = 0.040 for Cer 16:0; Spearman's r = 0.35, P = 0.026 for Cer 24:0), apolipoprotein B (Spearman's r = 0.33, P = 0.031 for Cer 16:0; Spearman's r = 0.48, P = 0.002 for Cer 24:0), and total cholesterol (Spearman's r = 0.34, P = 0.026 for Cer 16:0; Spearman's r = 0.31, P = 0.042 for Cer 24:0) after 12-week 320 mg/day anthocyanin administration. Besides, we found that anthocyanins at 320 mg/day also markedly enhanced cholesterol efflux capacity in the dyslipidemia, the changes of which were positively associated with the reductions in Cer 16:0 (Spearman's r = 0.42, P = 0.006) independent of HDL-C and apolipoprotein A-I.
Reductions in plasma Cer 16:0 and Cer 18:0 after 12-week anthocyanin intervention were dose-dependently associated with improvements in plasma lipids and cholesterol efflux capacity in the dyslipidemia.
The study was registered at ClinicalTrials.gov with the identifier No. NCT03415503.
血浆神经酰胺已被确定为代谢和心血管疾病的新的危险因素。我们旨在评估饮食中花青素对血浆神经酰胺的影响，并阐明这些神经酰胺的变化是否与血脂异常中其他心血管代谢风险因素的变化有关。
在一项随机、双盲、安慰剂对照试验中，176 名符合条件的血脂异常患者被随机分为四组，分别接受安慰剂、40、80 或 320mg/天的花青素，干预 12 周。
共有 169 名患者完成了研究。经过 12 周的干预，饮食中的花青素剂量依赖性地降低了血脂异常患者的所有六种神经酰胺的血浆浓度（所有 P 值均<0.05）。具体来说，320mg/天的花青素可有效降低血浆 N-棕榈酰鞘氨醇（Cer 16:0，平均变化：-28.3±41.2 与 2.9±38.2，nmol/L，P=0.018）和 N-二十四酰鞘氨醇（Cer 24:0，平均变化：-157.1±493.9 与 10.7±439.9，nmol/L，P=0.002）与安慰剂相比。血浆 Cer 16:0 和 Cer 24:0 的下降与血浆非高密度脂蛋白胆固醇（非 HDL-C）、载脂蛋白 B 和总胆固醇的降低显著相关（Spearman's r=0.32，P=0.040 用于 Cer 16:0；Spearman's r=0.35，P=0.026 用于 Cer 24:0），在接受 320mg/天花青素治疗 12 周后。此外，我们发现 320mg/天的花青素还显著增强了血脂异常患者的胆固醇外排能力，其变化与 Cer 16:0 的降低呈正相关（Spearman's r=0.42，P=0.006），与 HDL-C 和载脂蛋白 A-I 无关。
12 周花青素干预后血浆 Cer 16:0 和 Cer 18:0 的降低与血脂异常患者的血浆脂质和胆固醇外排能力的改善呈剂量依赖性相关。
该研究在 ClinicalTrials.gov 注册，标识符为 NCT03415503。
